Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of Glenmark Pharmaceuticals Ltd. ('GPL'), in their meeting held on January 31, 2014, have approved a proposal to merge its subsidiaries i.e. Glenmark Generics Ltd. ('GGL') and Glenmark Access Ltd. ('GAL') with GPL. The merger will be effected through a court approved Scheme of Amalgamation under Sections 391 to 394 and other applicable provisions of the Companies Act, 1956 ('Scheme'). As on date 99.33% of the share capital of GGL is being held by GPL (including 1.19% being held by GAL, a wholly owned subsidiary of GPL). Per the Scheme, the remaining shareholders holding 0.67% (10,16,741 equity shares) of the share capital of GGL will be issued shares of GPL at a swap ratio which has been determined as 4 shares of GPL of Re. 1 each for every 5 shares of Rs. 10 each held by the shareholders of GGL. Glenmark Pharmaceuticals Ltd has informed BSE that the Hon'ble Bombay High Court has on March 20, 2015 orally pronounced an Order, approving the scheme of amalgamation of Glenmark Generics Limited and Glenmark Access Limited with Glenmark Pharmaceuticals Limited under Sections 391 to 394 of the Companies Act, 1956. Further the certified true copy of the said Order is being awaited and the scheme of amalgamation will only be effective after the order has been filed with the Registrar of Companies. (As Per BSE Announcement Dated on 20.03.2015) Glenmark Pharmaceuticals Ltd has informed BSE that the certified copy of order of the Hon'ble High Court of Judicature at Bombay ('Court Order') approving the Scheme of Amalgamation of Glenmark Generics Limited and Glenmark Access Limited with Glenmark Pharmaceuticals Limited are being filed by the respective Companies with the Registrar of Companies, Mumbai, Maharashtra ('ROC') on April 10, 2015. With the filing of the Court Order with the ROC, Glenmark Generics Limited and Glenmark Access Limited would stand dissolved without being wound up and the Scheme would become effective as on April 10, 2015. (As per BSE Announcement Dated on 10.04.2015) Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on June 16, 2015, allotted 17,803 Equity Shares of the face value of Re. 1/- each in the ratio of Four (4) Equity Shares of Re. 1 each of Glenmark Pharmaceuticals Limited for every Five (5) Equity Shares of Rs. 10/- each held of Glenmark Generics Limited pursuant to Scheme of Amalgamation of Glenmark Generics Limited with Glenmark Pharmaceuticals Limited approved by Hon'ble High Court of Bombay. (As Per BSE Announcement Dated on 16.06.2015)